Placebo/CP-690,550

DRUG2 trials

Sponsors

Pfizer

Conditions

Psoriasis

Phase 3

A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis

CompletedNCT01276639

PfizerPsoriasis

Start: 2011-03-31End: 2013-04-30Updated: 2014-09-19

A One-Year Study To Evaluate The Efficacy And Safety Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis

CompletedNCT01309737

PfizerPsoriasis

Start: 2011-03-31End: 2013-04-30Updated: 2014-09-19

Related Papers

Risk Stratification of Patients with Psoriatic Arthritis and Ankylosing Spondylitis for Treatment with Tofacitinib: A Review of Current Clinical Data.

2024-05-025 citations

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib

Therapeutic Advances in Musculoskeletal Disease2023-01-0119 citations

Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials.

2020-08-2013 citations

Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis.

2017-06-2450 citations

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis

Journal of the American Academy of Dermatology2017-04-0795 citations

Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis.

2016-09-2845 citations

Early clinical response to tofacitinib treatment as a predictor of subsequent efficacy: Results from two phase 3 studies of patients with moderate-to-severe plaque psoriasis

Journal of Dermatological Treatment2016-08-1816 citations

PT070 Assessment of Lipidic Indexes in the Prediction of Systolic and Diastolic Blood Pressure in a Sample of Mexican Population

Global Heart2016-06-01

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

2015-10-01231 citations

Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

2015-05-0830 citations